
Procter & Gamble Health Ltd
NSE:PGHL

Intrinsic Value
The intrinsic value of one
PGHL
stock under the Base Case scenario is
3 082.37
INR.
Compared to the current market price of 5 579 INR,
Procter & Gamble Health Ltd
is
Overvalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Procter & Gamble Health Ltd
Fundamental Analysis


Revenue & Expenses Breakdown
Procter & Gamble Health Ltd
Balance Sheet Decomposition
Procter & Gamble Health Ltd
Current Assets | 6.1B |
Cash & Short-Term Investments | 2.9B |
Receivables | 1.3B |
Other Current Assets | 1.9B |
Non-Current Assets | 2.6B |
Long-Term Investments | 17.3m |
PP&E | 1.3B |
Intangibles | 8.4m |
Other Non-Current Assets | 1.3B |
Free Cash Flow Analysis
Procter & Gamble Health Ltd
INR | |
Free Cash Flow | INR |
Earnings Waterfall
Procter & Gamble Health Ltd
Revenue
|
11.6B
INR
|
Cost of Revenue
|
-3.2B
INR
|
Gross Profit
|
8.4B
INR
|
Operating Expenses
|
-5.4B
INR
|
Operating Income
|
3.1B
INR
|
Other Expenses
|
-710.8m
INR
|
Net Income
|
2.4B
INR
|
PGHL Profitability Score
Profitability Due Diligence
Procter & Gamble Health Ltd's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

Score
Procter & Gamble Health Ltd's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
PGHL Solvency Score
Solvency Due Diligence
Procter & Gamble Health Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

Score
Procter & Gamble Health Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PGHL Price Targets Summary
Procter & Gamble Health Ltd
Dividends
Current shareholder yield for PGHL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
PGHL
stock under the Base Case scenario is
3 082.37
INR.
Compared to the current market price of 5 579 INR,
Procter & Gamble Health Ltd
is
Overvalued by 45%.